Singh Life Science Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 2.50 M
as on 24-10-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.42 Cr
as on 24-10-2024
- Satisfied Charges ₹ 0.55 M
as on 24-10-2024
- Revenue 127.87%
(FY 2023)
- Profit -72.06%
(FY 2023)
- Ebitda 68.52%
(FY 2023)
- Net Worth 1.43%
(FY 2023)
- Total Assets 44.42%
(FY 2023)
About Singh Life Science
The Corporate was formerly known as Simple Petech Private Limited. The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.42 Cr. The company has closed loans amounting to ₹0.55 M, as per Ministry of Corporate Affairs (MCA) records.
Hardeep Chawla, Meena Dheeman, and Umashankar Jha serve as directors at the Company.
- CIN/LLPIN
U24230MP2004PLC016614
- Company No.
016614
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 May 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Dhar, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Singh Life Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hardeep Chawla  | Director | 07-Dec-2009 | Current |
| Meena Dheeman | Director | 13-Aug-2018 | Current |
| Umashankar Jha | Director | 30-Sep-2018 | Current |
Financial Performance of Singh Life Science.
Singh Life Science Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 127.87% increase. The company also saw a substantial fall in profitability, with a 72.06% decrease in profit. The company's net worth moved up by a moderate rise of 1.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Singh Life Science?
In 2023, Singh Life Science had a promoter holding of 66.24% and a public holding of 33.76%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Kar's Techno Plast Private LimitedActive 11 years 7 months
Hardeep Chawla and Meena Dheeman are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jul 2007 | ₹1.42 Cr | Open |
Punjab National Bank Creation Date: 08 Aug 2014 | ₹0.55 M | Satisfied |
How Many Employees Work at Singh Life Science?
Unlock and access historical data on people associated with Singh Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Singh Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Singh Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
